Bamlanivimab

Eli Lilly and Co (NYSE: LLY)’s antibody treatments have received an emergency use authorization from the United States Food and Drug Administration. What Happened: The federal regulator issued the EUA for the two drugs, bamlanivimab and etesevimab, to be administered together for the...

The United States Food and Drug Administration has issued an emergency use authorization for Eli Lilly and Company’s (NYSE: LLY) monoclonal antibody treatment bamlanivimab for use against COVID-19 in both adults and children. What Happened: Under the EUA, the treatment can be distributed and...

Eli Lilly and Company (NYSE: LLY) said Monday that a trial of its antibody treatment for use in hospitalized COVID-19 patients has come to an end as the treatment is unlikely to help such patients.  What Happened: The one of its kind study — conducted by the National Institute of Allergy...